Despite recent efforts, prostate cancer (PCa) remains one of the most common cancers in
men. Currently, there is no effective treatment for castration-resistant prostate cancer …

Objectives To explore healthcare professional perceived barriers and facilitators to
discussing sexual health and wellbeing with patients after diagnosis of chronic illness …

Background Little is known about health-related quality of life (HRQOL) following treatment
for bladder cancer (BC). Objective To determine this, we undertook a cross-sectional survey …

After the widespread adoption of prostate-specific antigen (PSA) screening in the early
1990s, prostate cancer diagnoses increased rapidly while death rates halved over the …

Screening with a prostate-specific antigen (PSA) test could reduce death from prostate
cancer in some men but at the cost of substantial numbers overdiagnosed, as well as false …

Background In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT)
versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall …

Background Few studies have evaluated mental health disorders comprehensively among
patients with prostate cancer on long-term follow-up. The primary aim of our study was to …

Context In response to growing concerns over rising costs and major variation in quality,
improving value for patients has been proposed as a fundamentally new strategy for how …

Background With the growing notion of patient-focused drug development, the quality of life
and other patient-reported outcomes (PROs) of cancer patients are gaining considerable …

Objective Clinical options for managing nonmetastatic prostate cancer (PCa) vary. Each
option has side effects associated with it, leading to difficulty in decision‐making. This study …